华海药业：“卡络磺钠注射液”取得药品注册证书

Core Viewpoint - Huahai Pharmaceutical has received the drug registration certificate for Carbenoxolone Sodium Injection from the National Medical Products Administration, which is expected to impact its revenue positively in the upcoming year [1] Company Summary - Huahai Pharmaceutical's revenue composition for the year 2024 is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - As of the report date, Huahai Pharmaceutical has a market capitalization of 33.6 billion yuan [1]